P-49 Major adverse cardiovascular events and hyperuricemia during treatment of tuberculosis = P-49 Major adverse cardiovascular events and hyperuricemia during treatment of tuberculosis

다국어 초록 (Multilingual Abstract)

Background: Hyperuricemia is common drug effect during treatment of tuberculosis consisting pyrazinamide (PZA). However, it is unclear the relationship between PZA-induced hyperuricemia and major adverse cardiovascular events (MACE). Aim: We evaluated the relationship between MACE and hyperuricemia in patients treated with PZA-based antituberculous drugs.
Methods: We retrospectively reviewed the medical charts of patients who treated with tuberculosis at Chonnam National University Hospital between January 2010 and June 2017.
Results: Total 1,674 patients were treated with tuberculosis. Among them, 229 patients were excluded due to lack of available serum uric acid levels because of early follow-up loss or local transfer. Mean age was 57.9 and 887 patients (61.4%) were male. Most patients (75.6%) who treated with tuberculosis were diagnosed pulmonary tuberculosis. The initial standard treatment regimens of isoniazid, rifampin, ethambutol, and PZA were introduced to most patients (92.9%). Among them, 61.9% patients at 2 weeks and 59.5% at 2 months form starting treatment had hyperuricemia. MACE were occured only 17 patients (1.2%) during treatment. There was no relationship between hyperuricemia and MACE in the univariate analysis (odds ratio, 0.72; 95% confidence interval, 0.18─2.90; P=0.648).
Conclusion: Most patients who received PZA-based antituberculous drugs had hyperuricemia, however, it was not associated with development of MACE.